![\"Genetic](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/06\/01JXW9V1HS969GYN7E0BXXR3ZJ-3672c7.jpg\")
<\/p>\n <\/p>\n
A new study aims to show how genetic testing could help personalise treatments by boosting medication response and reducing harmful side effects.<\/p>\n
A new study aims to show how genetic testing could help personalise treatments by boosting medication response and reducing harmful side effects.<\/p>\n
The landmark trial will recruit up to 4,000 patients over the next two years in the NHS Greater Glasgow and Clyde area, to investigate how an individual\u2019s genetic profile affects their response to 60 common medications.<\/p>\n
It is hoped the Phoenix Study will to lead to wider implementation of genetic testing across Scotland, making \u201cprecision medicine\u201d routine, for the first time.<\/p>\n
Researchers hope it will pave the way for tailored prescribing across cardiology, stroke, surgery, orthopaedics, geriatrics, gynaecology, ENT, rheumatology, respiratory, neurology, psychiatry and other specialities.<\/p>\n
The trial will take place at the Queen Elizabeth University Hospital (QEUH) in Glasgow.<\/p>\n
Pharmacogenomics (PGx) \u2013 the study of how genes influence individual responses to drugs \u2013 has not been routinely used in clinical practice in the UK, amid hopes evidence will lead to change.<\/p>\n
Genetic test results will be sent to clinicians, allowing for treatment decisions to be adjusted, and patients will be followed up regularly to monitor the effects of any changes, to ensure they receive the highest standard of care.<\/p>\n
Patients will undergo a simple genetic test to analyse their DNA and the results, returned within days, will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their genetic make-up.<\/p>\n
Around 15% are expected to carry genetic variants that may reduce the effectiveness of a medication or increase the risk of side-effects.<\/p>\n
In some cases, the prescribed drug may be ineffective, or a different dosage may be needed.<\/p>\n
The trial is open to adult in-patients in the QEUH and patients will be randomly assigned to either receive the pharmacogenomic test immediately, or at three months, which will allow the researchers to establish evidence of benefit.<\/p>\n
Without prior testing, these issues can go unnoticed, often leading to a trial-and-error approach to treatment, according to researchers.<\/p>\n
It is led by Sandosh Padmanabhan, Pontecorvo chair of Pharmacogenomics at the University of Glasgow, in partnership with the University of Glasgow\u2019s Living Laboratory, the NHSGGC-hosted West of Scotland Innovation Hub, and industry partners MyDNA and Agena Bioscience.<\/p>\n
Patient Eric Balish was asked to take part by consultants, after having a heart attack and subsequent surgery.<\/p>\n
He was immediately prescribed clopidogrel, one of the 60 drugs included in the study, but has since had his medication changed a number of times.<\/p>\n
Mr Balish said: \u201cI knew a bit about personalised medicine previously, and so when I was asked to take part in the Phoenix Study I was happy to do it.<\/p>\n
\u201cIf you\u2019re asked to participate and support long-term research like this, then it\u2019s no great hardship to give something back and just do the right thing. I am hopeful my information can be of use to the trial and in the future.\u201d<\/p>\n
Prof Padmanabhan, a consultant at the QEUH, said: \u201cPhysicians and pharmacists increasingly recognise that PGx-informed prescribing and dispensing improves both the efficacy and safety of drug treatment.<\/p>\n
\u201cThe primary goal of this trial is to evaluate the clinical and\u00a0health-economic impact of PGx-guided prescribing.<\/p>\n
\u201cSpecifically, we want to determine if a PGx-guided approach to prescribing can significantly reduce the incidence and severity of drug related side-effects and\/or treatment failures.<\/p>\n
\u201cThis evaluation will compare the outcomes of participants who receive PGx-guided medication management to those receiving standard care.\u201d<\/p>\n
Dr Katriona Brooksbank, research and innovation lead for NHSGGC and the West of Scotland Innovation Hub, said: \u201cWe are incredibly excited to be supporting this trial, which could have a major impact on the treatments patients are prescribed based on their own genetics.<\/p>\n
\u201cIt will put precision medicine into action as researchers look to determine how a person\u2019s own genetic make-up can affect the drugs they are given as treatments.<\/p>\n
\u201cThis could allow clinicians to reduce adverse reactions and side effects, ensuring the best possible outcomes for patients.\u201d<\/p>\n
Allan Sheffield, co-founder of MyDNA, said: \u201cFor MyDNA, the Phoenix Study embodies the future of healthcare.<\/p>\n
\u201cOur unique combination of pharmacogenomic clinical decision support and in-house Gene by Gene accredited testing empowers clinicians to move beyond guesswork.<\/p>\n
\u201cThis trial will demonstrate the profound impact of precision medicine, paving the way for a future where this approach routinely drives better patient outcomes.\u201d<\/p>\n
Published: 17\/06\/2025 by Radio NewsHub <\/p>\n","protected":false},"excerpt":{"rendered":"A new study aims to show how genetic testing could help personalise treatments by boosting medication response and…\n","protected":false},"author":2,"featured_media":191443,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[267,70,16,15],"class_list":{"0":"post-191442","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-uk","11":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114698252899436684","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/191442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=191442"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/191442\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/191443"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=191442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=191442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=191442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}